European Sepsis Care Survey

June 11, 2023 updated by: Christian S. Scheer, MD, University Medicine Greifswald
The objective of this survey is to investigate the current state of sepsis care around Europe. The study is aiming at hospital structure, emergency departments, wards, intensive care units and clinical diagnostic and microbiological service.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
1450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Edegem, Belgium
        • Emergency Department Antwerp University Hospital
  • Czechia
      • Ostrava-Poruba, Czechia
        • Department of Anesthesiology and Intensive Care Medicine University Hospital of Ostrava
  • Denmark
      • Odense, Denmark
        • Department of Emergency Medicine University of Southern Denmark
  • Finland
      • Helsinki, Finland
        • Perioperative, Intensive Care and Pain Medicine Helsinki University Hospital
  • France
      • Garches, France
        • Hopital Raymond Poncare Service de Reanimation Medicale
  • Germany
      • Greifswald, Germany
        • University Medicine Greifswald
  • Greece
      • Athens, Greece
        • 4th Department of Internal Medicine ATTIKON University Hospital
  • Israel
      • Tel Aviv, Israel
        • National Institute for Antibiotic Resistance & Infection Control, Ministry of Health
  • Italy
      • Milan, Italy
        • Ospedale Niguarda Ca' Granda Milano
  • Moldova, Republic of
      • Chișinău, Moldova, Republic of
        • State University of Medicine and Pharmaceutics "Nicolae Testemiţanu"
  • Netherlands
      • Groningen, Netherlands
        • University Medical Center Groningen
  • Norway
      • Trondheim, Norway
        • St Olavs Hospital
  • Poland
      • Wrocław, Poland
        • Department of Anaesthesiology and Intensive Therapy Wroclaw Medical University
  • Portugal
      • Porto, Portugal
        • Universidade do Porto Faculdade de Medicina: Porto
  • Romania
      • Bucharest, Romania
        • "Prof CC Iliescu" Emergency Institute for Cardiovascular Diseases, Bucharest
  • Russian Federation
      • St. Petersburg, Russian Federation
        • Vladimir L. Vanevskii Department of Anaesthesiology and Reanimatology, North-Western State Medical University named after Ilya I. Mechnikov
  • Spain
      • Sabadell, Spain
        • Corporació Sanitària Parc Taulí · critical care center, sabadell hospital, Corporació Sanitaria Universitaria Parc Tauli
  • Sweden
      • Lund, Sweden
        • Faculty of Medicine, Department of Clinical Sciences Lund, Division of Infection Medicine, Lund University
  • Turkey
      • Ankara, Turkey
        • Hacettepe University, Department of Internal Medicine Sihhiye, Ankara
  • United Kingdom
      • London, United Kingdom
        • King's College London, Guy's and St Thomas' Foundation Hospital, Department of Critical Care, London

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

European hospitals

Description

Inclusion Criteria:

  • Hospitals of all strata

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Questionnaire
Time Frame: 2021
Structure of sepsis care in Europe
2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University Medicine Greifswald

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
European Society of Intensive Care Medicine
Becton, Dickinson and Company
European Sepsis Alliance
European Society for Emergency Medicine (EUSEM) Research Network
European Society of Clinical Microbiology and Infectious Diseases, ESGBIES Study Group
Sepsisdialog, Germany
European Shock Society
European Society of Anaesthesiology and Intensive Care

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Christian S Scheer, Anesthesiology and Intensive Care Medicine Department, University of Greifswald, Germany
  • Principal Investigator: Adam Linder, European Sepsis Alliance
  • Principal Investigator: Daniela Filipescu, European Sepsis Alliance, European Society of Anaesthesiology and Intensive Care
  • Principal Investigator: Evangelos Giamarellos-Bourboulis, European Sepsis Alliance, European Shock Society
  • Principal Investigator: Evgeny Idelevich, ESCMID/Study Group for Bloodstream Infections, Endocarditis and Sepsis
  • Principal Investigator: Konrad Reinhart, Global Sepsis Alliance
  • Principal Investigator: Matthias Gründling, Quality management project Sepsisdialog
  • Principal Investigator: Ricard Ferrer, European Society of Intensive Care medicine
  • Principal Investigator: Said Laribi, European Society for Emergency Medicine (EUSEM) Research Network
  • Principal Investigator: Manu Malbrain, International Fluid Academy
  • Principal Investigator: Gabriella Bottari, European Society of Paediatric and Neonatal Intensive Care

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 1, 2021

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 30, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
October 30, 2022

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 31, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 17, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 28, 2021

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 13, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 11, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ESA_Survey01
  • BB 124/21 (Other Identifier: Ethics Committee University Medicine Greifswald)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

This study uses no patient data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings